Brian Lee Frederick

US Patent:

8106154, Jan 31, 2012

Filed:

Jan 30, 2008

Appl. No.:

12/022926

Inventors:

Christopher P. Holmes - Saratoga CA, US
Anjan Chakrabarti - Gurgoan, IN
Brian T. Frederick - Ben Lomond CA, US
Yijun Pan - Union City CA, US
Yaohua S. Dong - San Francisco CA, US
Ashok Bhandari - Cupertino CA, US

Assignee:

Affymax, Inc. - Palo Alto CA

International Classification:

C07K 7/02
C07K 7/08
C07K 14/505
C07C 233/05
C07C 229/04
A61K 38/19

US Classification:

530323, 53038823, 530421, 562567, 564192, 514 77

Abstract:

Compounds comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety are disclosed. Various linker moieties for use in these compounds are also disclosed, along methods for their synthesis.

US Patent:

20070203066, Aug 30, 2007

Filed:

Dec 8, 2006

Appl. No.:

11/636353

Inventors:

Christopher Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Genet Zemede - Santa Clara CA, US
Yvonne Angell - San Jose CA, US
Brian Frederick - Ben Lomond CA, US
Caiding Xu - San Jose CA, US

International Classification:

A61K 38/10
A61K 38/08
C07K 7/08
C07K 7/06

US Classification:

514012000, 514013000, 514014000, 514015000, 514016000, 530326000, 530328000, 530327000, 530329000

Abstract:

Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise peptide molecules, optionally containing one or more individual peptide chains covalently linked, and optionally modified with polyethylene glycol (PEG). The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized, metastasized tumors is useful for preventing the growth or expansion of such tumors.

US Patent:

20080108564, May 8, 2008

Filed:

Apr 13, 2007

Appl. No.:

11/735106

Inventors:

Christopher P. Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Genet Zemede - San Jose CA, US
Ashok Bhandari - Cupertino CA, US
Yaohua S. Dong - San Francisco CA, US
David Tumelty - San Diego CA, US
Guy Lalonde - Woodside CA, US
Brian T. Frederick - Ben Lomond CA, US
Anjan Chakrabarti - Gurgaon, IN
Palani Balu - Cupertino CA, US
Peter J. Schatz - Cupertino CA, US
Nicholas C. Wrighton - Winchester MA, US
William J. Dower - Menlo Park CA, US

Assignee:

Affymax, Inc. - Palo Alto CA

International Classification:

A61K 38/16
C07K 7/06
C07K 7/08
C07K 14/00
A61P 37/00
A61P 35/00
A61P 7/00
A61K 38/08
A61K 38/10

US Classification:

514 12, 530326, 530327, 530324, 530328, 514 13, 514 14, 514 16

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

US Patent:

20090005292, Jan 1, 2009

Filed:

Nov 11, 2005

Appl. No.:

11/718998

Inventors:

Christopher P. Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Genet Zemede - San Jose CA, US
Ashok Bhandari - Cupertino CA, US
David Tumelty - San Diego CA, US
Guy Lalonde - Woodside CA, US
Palani Balu - Cupertino CA, US
Peter J. Schatz - Cupertino CA, US
William J. Dower - Menlo Park CA, US
Anjan Chakrabarti - Gurgaon, IN
Yaohua S. Dong - San Francisco CA, US
Brian T. Frederick - Ben Lomond CA, US
Nicholas C. Wrighton - Winchester MA, US

Assignee:

AFFYMAX, INC. - Palo Alto CA

International Classification:

A61K 38/02
C07K 2/00
A61P 7/00
A61P 35/00
A61P 37/00

US Classification:

514 2, 530350

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

US Patent:

20110282029, Nov 17, 2011

Filed:

Dec 10, 2010

Appl. No.:

12/965167

Inventors:

Christopher P. Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Genet Zemede - San Jose CA, US
Ashok Bhandari - Cupertino CA, US
Yaohua S. Dong - San Francisco CA, US
David Tumelty - San Diego CA, US
Guy Lalonde - Woodside CA, US
Brian T. Frederick - Ben Lomond CA, US
Anjan Chakrabarti - Gurgaon, IN
Palani Balu - Cupertino CA, US
Peter J. Schatz - Cupertino CA, US
Nicholas C. Wrighton - Winchester MA, US
William J. Dower - Menlo Park CA, US

Assignee:

AFFYMAX, INC. - Palo Alto CA

International Classification:

C07K 7/08
C07K 14/00

US Classification:

530323, 530327, 530326, 530324

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

US Patent:

20120157660, Jun 21, 2012

Filed:

Aug 18, 2010

Appl. No.:

12/859204

Inventors:

Christopher P. Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Genet Zemede - San Jose CA, US
Ashok Bhandari - Cupertino CA, US
David Tumelty - San Diego CA, US
Guy Lalonde - Woodside CA, US
Palani Balu - Cupertino CA, US
Peter J. Schatz - Cupertino CA, US
William J. Dower - Menlo Park CA, US
Anjan Chakrabarti - Gurgaon, IN
Yaohua S. Dong - San Francisco CA, US
Brian T. Frederick - Ben Lomond CA, US
Nicholas C. Wrighton - Winchester MA, US

Assignee:

AFFYMAX, INC. - Palo Alto CA

International Classification:

C07K 14/00
C07K 7/08

US Classification:

530324, 530326, 530327

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

US Patent:

20120165275, Jun 28, 2012

Filed:

Dec 21, 2011

Appl. No.:

13/333570

Inventors:

Christopher P. Holmes - Saratoga CA, US
Anjan Chakrabarti - Gurgaon, IN
Brian T. Frederick - Ben Lomond CA, US
Yijun Pan - Fremont CA, US
Yaohua S. Dong - San Francisco CA, US
Ashok Bhandari - Cupertino CA, US

Assignee:

AFFYMAX, INC. - Palo Alto CA

International Classification:

A61K 38/16
C07K 14/00
C07D 207/46
C07D 207/12

US Classification:

514 214, 548520, 530326, 548542

Abstract:

Compounds comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety are disclosed. Various linker moieties for use in these compounds are also disclosed, along methods for their synthesis.

US Patent:

20130012685, Jan 10, 2013

Filed:

Jul 3, 2012

Appl. No.:

13/541420

Inventors:

Christopher P. Holmes - Saratoga CA, US
Qun Yin - Palo Alto CA, US
Genet Zemede - San Jose CA, US
Ashok Bhandari - Cupertino CA, US
Yaohua S. Dong - San Francisco CA, US
David Tumelty - San Diego CA, US
Guy Lalonde - Woodside CA, US
Brian T. Frederick - Ben Lomond CA, US
Anjan Chakrabarti - Gurgaon, IN
Palani Balu - Cupertino CA, US
Peter J. Schatz - Cupertino CA, US
Nicholas C. Wrighton - Winchester MA, US
William J. Dower - Menlo Park CA, US

Assignee:

AFFYMAX, INC. - Palo Alto CA

International Classification:

C07K 7/00
C07K 14/00

US Classification:

530326, 530327

Abstract:

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.